(NP (NP Retinoid/NN differentiation/NN therapy/NN) (PP in/IN (NP promyelocytic/JJ leukemia/NN)) ./.)
(S (NP-SBJ (NP Acute/JJ promyelocytic/JJ leukemia/NN) (PRN -LRB-/-LRB- (NP APL/NN) -RRB-/-RRB-)) (VP is/VBZ (NP-PRD (NP a/DT specific/JJ type/NN) (PP of/IN (NP acute/JJ myeloid/JJ leukemia/NN)) (VP characterized/VBN (NP */-NONE-) (PP by/IN (NP-LGS-COOD (NP (NP the/DT morphology/NN) (PP of/IN (NP the/DT blast/NN cells/NNS))) ,/, (NP a/DT specific/JJ t-LRB-15;17-RRB-/NN translocation/NN) ,/, and/CC (NP (NP risks/NNS) (PP of/IN (NP definite/JJ coagulopathy/NN)))))))) ./.)
(S (ADVP-TMP Recently/RB) (NP-SBJ-72 this/DT leukemia/NN) (VP was/VBD (VP (ADVP further/RB) characterized/VBN (NP *-72/-NONE-) (PP by/IN (NP-LGS-COOD (NP (NP an/DT exquisite/JJ sensitivity/NN) (PP to/TO (NP (NP all-trans/JJ retinoic/JJ acid/NN 's/POS) differentiation/NN effect/NN))) and/CC (NP (NP the/DT production/NN) (PP of/IN (NP (NP a/DT fusion/NN gene/NN) (VP altering/VBG (NP-COOD (NP (NP the/DT gene/NN) (PP of/IN (NP RARalpha/NN))) and/CC (NP a/DT novel/JJ gene/NN PML/NN)))))))))) ./.)
(S (NP-SBJ (NP (ADJP In/FW vivo/FW) differentiation/NN therapy/NN) (PP with/IN (NP retinoids/NNS)) (PP in/IN (NP APL/NN patients/NNS))) (VP follows/VBZ (NP (NP strict/JJ guidelines/NNS) (ADJP related/JJ (PP both/CC to/TO (NP-COOD (NP the/DT APL/NN cell/NN) and/CC (NP (NP the/DT biodisposal/NN) (PP of/IN (NP all-trans/JJ retinoic/JJ acid/NN)))))))) ./.)
